An Update on Overall Survival (Os) and Follow-On Therapies in Break-3, a Phase Iii, Randomized Trial: Dabrafenib (D) Vs. Dacarbazine (Dtic) in Patients (Pts) with Braf V600E Mutation-Positive Metastatic Melanoma (Mm)
Axel Hauschild(University Hospital Schleswig-Holstein), Paul B. Chapman(Memorial Sloan Kettering Cancer Center), Patricia Haney(GlaxoSmithKline (United States)), Jeffrey J. Legos(Novartis (United States)), Salvador Martín‐Algarra(Clinica Universidad de Navarra), Fan Jin(Second Affiliated Hospital of Xi'an Jiaotong University), Gursel Aktan(Merck & Co., Inc., Rahway, NJ, USA (United States)), Wilson H. Miller(Jewish General Hospital), Thomas Jouary(Hôpital Saint-André), J. Grobb, Cornelia Mauch(University Hospital Cologne), Piotr Rutkowski(The Maria Sklodowska-Curie National Research Institute of Oncology), Bogusława Karaszewska(State University of Applied Sciences in Konin), Christian U. Blank(The Netherlands Cancer Institute), S. Swann(GlaxoSmithKline (United States)), Lev Demidov(Heidelberg University), Michael Millward(University of Western Australia), Ralf Gutzmer(University Hospitals of the Ruhr-University of Bochum)
Cited by 37
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET
|Nature Medicine|2012|3.7k
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
|New England Journal of Medicine|2010|3.5k